Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery.
Although the question of optimal treatment for malignant gliomas has been addressed in many retrospective papers, no clear answer has been found to what extent surgical removal of tumor tissue should be performed. We conducted a retrospective analysis in 274 unselected patients, admitted to our institution with the diagnosis of malignant supratentorial glioma. Median survival time after surgery was analyzed with respect to the following defining variables: Age, pre- and postoperative Karnofsky Performance Scale (KPS), tumor location, histology, sex, pre- and postoperative tumor volume and volumetrically measured extent of resection. All these defining variables with exception of sex and preoperative tumor volume were of significant influence on the median survival time of glioma patients (Kolmogoroff-Smirnoff test, Log-Rank test, Breslow test and Tarone-Ware test p < 0,05). To exclude covariant influences of these variables on patients survival and to answer the question of the best surgical option, a matched pair analysis between 40 patients undergoing stereotactic biopsy and 40 patients undergoing cytoreductive surgery was performed. Median survival time (MST) in the biopsy group was 184 days whereas the cytoreductive surgery group had a MST of 292 days (p < 0,05). In addition median postoperative KPS at the point of discharge in patients with tumor resection was slightly better (KPS 58%) in comparison with the biopsy group (KPS 53%) but not on a significant level. It is concluded from these data that patients harbouring malignant gliomas clearly benefit from cytoreductive surgery compared with stereotactic biopsy regarding life expectancy and mildly regarding life quality.